Last reviewed · How we verify
Sodium Nitrite Inhalation Solution
At a glance
| Generic name | Sodium Nitrite Inhalation Solution |
|---|---|
| Also known as | AIR001 Inhalation Solution, AIR001, NaNO2, Sodium Nitrite |
| Sponsor | Aires Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT) (PHASE2, PHASE3)
- Inhaled Nitrite in Subjects With Pulmonary Hypertension (PHASE2)
- Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction (PHASE2)
- A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH) (PHASE2)
- Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects (PHASE1)
- Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sodium Nitrite Inhalation Solution CI brief — competitive landscape report
- Sodium Nitrite Inhalation Solution updates RSS · CI watch RSS
- Aires Pharmaceuticals, Inc. portfolio CI